1431-40-9

Usage

Uses

Used in Pharmaceutical Industry:
2-methylsulfanylpyrimidine-4,5,6-triamine is used as an active pharmaceutical ingredient for its anti-tumor, anti-microbial, and anti-inflammatory properties. Its diverse biological activities make it a promising candidate for the development of new drugs to treat various diseases.
Used in Agrichemical Industry:
In the agrichemical industry, 2-methylsulfanylpyrimidine-4,5,6-triamine is used as a bioactive compound for its potential anti-microbial and anti-inflammatory properties. It can be utilized in the development of pesticides, fungicides, and other agrochemicals to protect crops and enhance agricultural productivity.
Used as a Key Intermediate:
2-methylsulfanylpyrimidine-4,5,6-triamine is also used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and functional groups make it an important building block for the creation of new molecules with potential applications in various fields of research and industry.

InChI:InChI=1/C5H9N5S/c1-11-5-9-3(7)2(6)4(8)10-5/h6H2,1H3,(H4,7,8,9,10)

Upstream product

• 52222-43-2 2-(methylthio)-5-nitrosopyrimidine-4,6-diamine 
• 1005-38-5 4-amino-6-chloro-2-methylthiopyrimidine 
• 1005-39-6 4,6-diamino-2-methylthiopyrimidine 

Downstream Products

• 94543-82-5 N-{4-[(4-amino-2-methylsulfanyl-pteridin-6-ylmethyl)-amino]-benzoyl}-DL-glutamic acid 
• 93898-79-4 4-[(4-amino-2-methylsulfanyl-pteridin-6-ylmethyl)-amino]-benzoic acid 
• 15263-43-1 2-methylsulfanyl-6,7-diphenyl-pteridin-4-ylamine 
• 1402415-41-1 C₂₂H₂₁N₅O₃S 
• 1402415-43-3 C₂₂H₁₈F₃N₅O₂S 
• 1402415-39-7 C₂₁H₁₉N₅O₂S 
• 1402415-38-6 C₂₁H₁₈ClN₅O₂S 
• 1198-83-0 2-(methylthio)-7H-purin-6-amine 
• 6306-87-2 7-amino-5-methylthio-[1,2,5]thiadiazolo[3,4-d]pyrimidine 

Relevant academic research and scientific papers

Pteridines: Synthesis and characteristics of 5,6-dihydro-6-(1,2,3-trihydroxypropyl)pteridines: Covalent intramolecular adducts

Various 5,6-diaminopyrimidines (1, 15, 24, 33) were condensed with the phenylhydrazones of L-(2) and D-arabinose (3) in acidic medium under N2 to give formal 5,6-dihydro-6-(1,2,3-trihydroxypropyl)pteridines (see, e.g., 4 and 5), the latter turned out to exist preferentially as intramolecular adducts, the hexahydropyrano-[3,2-g]pteridines 6, 7, 16, 17, 25, 26, and 34, formed subsequently by addition of the terminal OH group of the side-chain to the C(7)=N(8) bond of the pteridine moiety. Spectroscopically, the isomeric hexahydrofuro [3,2-g]pteridines 10, 11, 18, 19, and 35 were also detected as minor components in the equilibrium mixtures. In the 4-amino-2-(methylthio)pteridine series, crystallization of 6 and 7 led to the stereochemically pure (3S,4R,4aR,10aS)-6-amino-3,4,4a,5,10,10a-hexahydro-8-(methylthio -2H-pyrano[3,2-g]pteridine-3,4-diol (8) and its corresponding enantiomer 9, respectively. Structure 8 was proven by X-ray analysis. Acylation of the hexahydropyrano[3,2-g]pteridines yielded the more stable tri-, tetra-, and pentaacetyl derivatives 12-14, 20-23, 27-32, and 37-39 which were characterized and of which the absolute and relative configurations were determined (1H- and 13C-NMR and UV spectra, chiroptical measurements, elemental analyses).

Imidazopyridine- and purine-thioacetamide derivatives: Potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1)

Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, nucleoside, and (di)phosphate levels. To study the (patho)physiological roles of NPP1 potent and selective inhibitors with drug-like properties are required. Therefore, a compound library was screened for NPP1 inhibitors using a colorimetric assay with p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP) as an artificial substrate. This led to the discovery of 2-(3H-imidazo[4,5-b]pyridin-2-ylthio)-N-(3,4-dimethoxyphenyl)acetamide (5a) as a hit compound with a Ki value of 217 nM. Subsequent structure-activity relationship studies led to the development of purine and imidazo[4,5-b]pyridine analogues with high inhibitory potency (Ki values of 5.00 nM and 29.6 nM, respectively) when assayed with p-Nph-5′-TMP as a substrate. Surprisingly, the compounds were significantly less potent when tested versus ATP as a substrate, with Ki values in the low micromolar range. A prototypic inhibitor was investigated for its mechanism of inhibition and found to be competitive versus both substrates.

Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: Structure-activity relationship of antagonists of (6R)-5,6,7,8- tetrahydrobiopterin cofactor

The family of nitric oxide synthases (NOS) catalyzes the conversion of L-arginine to L-citrulline and nitric oxide (NO), an important cellular messenger molecule which has been implicated in the pathophysiology of septic shock and inflammatory and neurode

Novel cephalosporin compounds and processes for the preparation thereof

The present invention relates to novel cephalosporin compounds, pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates and isomers thereof which possess potent and broad antibacterial activities. The compounds of the present invention have a (1,5,6-substituted-4-aminopyrimidinium-2-yl)thiomethyl group in 3-position of the cephem nucleus and is specifically represented by the following formula(I): ψψψ

9-Cyclohexyl-2-alkoxy-9H-adenine process

A process for preparing 9-cyclohexyl-2-alkoxy-9H-adenine derivatives such as 9-cyclohexyl-2-n-propoxy-9H-adenine from 7-amino-5-(methylthio)[1,2,5]oxadiazolo[3,4-d]pyrimidine and 7-amino-5-(methylthio)[1,2,5]thiadiazolo[3,4-d]pyrimidine is described. Othe